x

Coronavirus

Johnson & Johnson Has Begun a New Late-Stage Trial of Its Experimental COVID-19 Vaccine

November 17, 2020

NEW BRUNSWICK, N.J. — Johnson & Johnson has begun a new late-stage trial of its experimental COVID-19 vaccine, this time on a two-dose regimen.

J&J plans to give up to 30,000 people two doses of the vaccine. It’s been testing a one-dose regimen in a 60,000-person trial that began in late September and has enrolled nearly 10,000 volunteers so far.

In the new trial, volunteers will get either the vaccine or a dummy shot, then a second dose 57 days later, a company spokesman said Monday. That study is being conducted in the U.S., plus Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain and the UK — locations chosen because they have a high incidence of COVID-19 and can start testing quickly.

The company said it’s being “extremely thorough”’ by testing multiple doses and dosing regimens to evaluate long-term effectiveness.

A small, early-stage study of the vaccine found it triggered a strong immune response and was well tolerated.

RELATED

MACAO — Only a few tourists crisscrossed the wavy black and white paving of Macao's historic Senado Square on a recent weekday and many of the shops were shuttered.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.